Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Manometry | 1 | 2013 | 44 | 0.460 |
Why?
|
| Esophageal Achalasia | 1 | 2013 | 58 | 0.430 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 221 | 0.320 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 405 | 0.310 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 770 | 0.260 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2023 | 7 | 0.220 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2023 | 25 | 0.220 |
Why?
|
| Ethanol | 2 | 2023 | 250 | 0.200 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 350 | 0.200 |
Why?
|
| Oxadiazoles | 1 | 2021 | 38 | 0.200 |
Why?
|
| Colonic Polyps | 1 | 2022 | 130 | 0.200 |
Why?
|
| Indans | 1 | 2021 | 35 | 0.200 |
Why?
|
| Arteriosclerosis | 2 | 2002 | 112 | 0.190 |
Why?
|
| Intensive Care Units | 2 | 2021 | 389 | 0.190 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 59 | 0.190 |
Why?
|
| Pneumonia | 1 | 2022 | 183 | 0.180 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 45 | 0.180 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 65 | 0.180 |
Why?
|
| Lipoproteins | 1 | 2000 | 136 | 0.180 |
Why?
|
| Aortic Diseases | 1 | 2000 | 99 | 0.170 |
Why?
|
| Insulin Resistance | 1 | 2022 | 363 | 0.170 |
Why?
|
| Cholesterol | 1 | 2000 | 354 | 0.160 |
Why?
|
| Microbiota | 1 | 2023 | 396 | 0.150 |
Why?
|
| Oxygen | 1 | 2021 | 744 | 0.140 |
Why?
|
| Hospitalization | 1 | 2021 | 869 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 722 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 970 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1764 | 0.120 |
Why?
|
| Electric Impedance | 1 | 2013 | 110 | 0.110 |
Why?
|
| Liver | 3 | 2023 | 1241 | 0.110 |
Why?
|
| Aged | 6 | 2022 | 18904 | 0.100 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2011 | 26 | 0.100 |
Why?
|
| Gastrectomy | 1 | 2011 | 68 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2011 | 84 | 0.100 |
Why?
|
| Duodenum | 1 | 2011 | 102 | 0.090 |
Why?
|
| Stomach | 1 | 2011 | 110 | 0.090 |
Why?
|
| Humans | 11 | 2023 | 88482 | 0.070 |
Why?
|
| Male | 6 | 2022 | 41953 | 0.070 |
Why?
|
| Macrophage-1 Antigen | 1 | 2002 | 17 | 0.050 |
Why?
|
| Female | 6 | 2022 | 45687 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 74 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 74 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 80 | 0.050 |
Why?
|
| Bradycardia | 1 | 2021 | 39 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 69 | 0.050 |
Why?
|
| Serbia | 1 | 2021 | 3 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 8869 | 0.050 |
Why?
|
| Serum Albumin, Human | 1 | 2021 | 5 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 182 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 28 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 79 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 166 | 0.050 |
Why?
|
| Monocytes | 1 | 2002 | 217 | 0.050 |
Why?
|
| Diet, Atherogenic | 1 | 2000 | 15 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2021 | 149 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2022 | 274 | 0.050 |
Why?
|
| Middle Aged | 4 | 2022 | 25649 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6713 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 93 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 282 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 237 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 260 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 305 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 304 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 377 | 0.040 |
Why?
|
| Aging | 1 | 2022 | 710 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 26303 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 1489 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 726 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1712 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 961 | 0.040 |
Why?
|
| Hypertension | 1 | 2021 | 733 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1842 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2285 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2000 | 3198 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 5439 | 0.030 |
Why?
|
| Digestion | 1 | 2011 | 7 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 128 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 306 | 0.020 |
Why?
|
| Mice | 2 | 2002 | 11700 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 452 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 269 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 8151 | 0.020 |
Why?
|
| Animals | 2 | 2002 | 27203 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3653 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 1647 | 0.010 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2002 | 15 | 0.010 |
Why?
|
| Integrins | 1 | 2002 | 78 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 129 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 425 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 741 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1484 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 1790 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 1987 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2343 | 0.010 |
Why?
|